Showing 1 - 10 of 10 Items
Showing 1 - 10 of 10 Items
Sort By: Relevance
Journal Article
|Research
2024-09-12 • PLOS Medicine
2024-09-12 • PLOS Medicine
BACKGROUND
Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety an...
Conference Material
|Slide Presentation
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|Abstract
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Visceral leishmaniasis (VL) is a neglected tropical disease prevalent in populations affected by poverty, war, and famine. Without effective treatment, death is the norm...
Visceral leishmaniasis (VL) is a neglected tropical disease prevalent in populations affected by poverty, war, and famine. Without effective treatment, death is the norm...
Journal Article
|Review
2024-05-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2024-05-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene
Blood transfusion remains an important aspect of patient management in visceral leishmaniasis (VL). However, transfusion triggers considered are poorly understood. This review summarises...
Journal Article
|Protocol
2023-12-14 • BMJ Open
2023-12-14 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30,000 new cases occurring annually. Despite anaemia being a common haematological manifestation of ...
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30,000 new cases occurring annually. Despite anaemia being a common haematological manifestation of ...
Journal Article
|Protocol
2023-10-28 • BMJ Open
2023-10-28 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30 000 new cases occurring annually. There is an observed variation in the efficacy of the current f...
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30 000 new cases occurring annually. There is an observed variation in the efficacy of the current f...
Journal Article
|Research
2020-02-25 • BMC Medicine
2020-02-25 • BMC Medicine
BACKGROUND
The majority of Plasmodium falciparum malaria cases in Africa are treated with the artemisinin combination therapies artemether-lumefantrine (AL) and artesunate-amodiaquin...
The majority of Plasmodium falciparum malaria cases in Africa are treated with the artemisinin combination therapies artemether-lumefantrine (AL) and artesunate-amodiaquin...
Journal Article
|Review
2021-08-10 • PLOS Neglected Tropical Diseases
2021-08-10 • PLOS Neglected Tropical Diseases
BACKGROUND
Reports on the occurrence and outcome of Visceral Leishmaniasis (VL) in pregnant women is rare in published literature. The occurrence of VL in pregnancy is not systematic...
Reports on the occurrence and outcome of Visceral Leishmaniasis (VL) in pregnant women is rare in published literature. The occurrence of VL in pregnancy is not systematic...
Journal Article
|Research
2014-07-21 • American Journal of Tropical Medicine and Hygiene
2014-07-21 • American Journal of Tropical Medicine and Hygiene
Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin component and the partner drug. Polymorphisms in the Plasmodium falciparum chloroq...
Journal Article
|Research
2019-07-05 • Malaria Journal
2019-07-05 • Malaria Journal
BACKGROUND
Therapeutic efficacy studies in uncomplicated Plasmodium falciparum malaria are confounded by new infections, which constitute competing risk events since they can potenti...
Therapeutic efficacy studies in uncomplicated Plasmodium falciparum malaria are confounded by new infections, which constitute competing risk events since they can potenti...